Registro completo de metadatos
| Campo DC | Valor | Lengua/Idioma |
|---|---|---|
| dc.creator | Pérez Lloret, Santiago | - |
| dc.creator | Rascol, Olivier | - |
| dc.date | 2018-04-11T21:10:56Z | - |
| dc.date | 2018-04-11T21:10:56Z | - |
| dc.date | 2016-02 | - |
| dc.date | 2018-04-10T20:29:09Z | - |
| dc.date.accessioned | 2019-04-29T15:40:11Z | - |
| dc.date.available | 2019-04-29T15:40:11Z | - |
| dc.date.issued | 2018-04-11T21:10:56Z | - |
| dc.date.issued | 2018-04-11T21:10:56Z | - |
| dc.date.issued | 2016-02 | - |
| dc.date.issued | 2018-04-10T20:29:09Z | - |
| dc.identifier | Pérez Lloret, Santiago; Rascol, Olivier; The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease; Taylor & Francis; Expert Review of Neurotherapeutics; 16; 3; 2-2016; 245-258 | - |
| dc.identifier | 1744-8360 | - |
| dc.identifier | http://hdl.handle.net/11336/41809 | - |
| dc.identifier | CONICET Digital | - |
| dc.identifier | CONICET | - |
| dc.identifier.uri | http://rodna.bn.gov.ar:8080/jspui/handle/bnmm/299053 | - |
| dc.description | Safinamide (brand name Xadago®, Zambon S.p.A) is a third-generation reversible MAO-B inhibitor, which also blocks sodium voltage-sensitive channels and modulates stimulated release of glutamate. Safinamide was recently licensed by EMA for the treatment of PD as add-on therapy to a stable dose of levodopa alone or in combination with other PD medicinal products in mid-to advanced-stage fluctuating patients. It is also under review by the US FDA. Studies in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys and 6OHDA-lesioned rats suggest antiparkinsonian efficacy and antidyskinesic effects. Randomized, double-blind, placebo-controlled trials have shown efficacy for the treatment of motor symptoms in stable PD patients on dopamine agonists and in fluctuating PD patients on levodopa. Significant improvement in daily ON time was also observed in the latter. This effect was maintained for at least 2 years in double-blind conditions and, interestingly, without significant worsening of dyskinesia. Clinical studies have not detected any specific safety issue other than those already known with MAO-B inhibitors. | - |
| dc.description | Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina | - |
| dc.description | Fil: Rascol, Olivier. Universite Toulose 3; Francia. Inserm; Francia | - |
| dc.format | application/pdf | - |
| dc.format | application/pdf | - |
| dc.language | eng | - |
| dc.publisher | Taylor & Francis | - |
| dc.relation | info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1586/14737175.2016.1150783?journalCode=iern20 | - |
| dc.relation | info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1586/14737175.2016.1150783 | - |
| dc.rights | info:eu-repo/semantics/restrictedAccess | - |
| dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | - |
| dc.source | reponame:CONICET Digital (CONICET) | - |
| dc.source | instname:Consejo Nacional de Investigaciones Científicas y Técnicas | - |
| dc.source | instacron:CONICET | - |
| dc.subject | Enfermedad de PArkinson | - |
| dc.subject | Safinamida | - |
| dc.subject | Tratamiento | - |
| dc.subject | Inhibidores MAO-B | - |
| dc.subject | Medicina Critica y de Emergencia | - |
| dc.subject | Medicina Clínica | - |
| dc.subject | CIENCIAS MÉDICAS Y DE LA SALUD | - |
| dc.title | The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease | - |
| dc.type | info:eu-repo/semantics/article | - |
| dc.type | info:eu-repo/semantics/publishedVersion | - |
| dc.type | info:ar-repo/semantics/articulo | - |
| Aparece en las colecciones: | CONICET | |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.